Novo Nordisk revised earnings guidance for the year 2024. The company will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. This corresponds to an estimated negative impact of around 6% points on operating profit growth at CER in 2024 compared to the operating profit outlook communicated in the financial report for the period 1 January 2024 to 31 March 2024 (Company Announcement No 35/2024).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
919 DKK | -5.26% |
|
-5.86% | +31.64% |
05:11pm | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
01:48pm | Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.64% | 627B | |
+55.35% | 848B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B | |
+2.52% | 125B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Revises Earnings Guidance for the Year 2024